This is a Phase 3 study designed to evaluate the cardiovascular safety of the study medication compared to allopurinol in subjects with gout and significant cardiovascular comorbidities
The length of the study is expected to be approximately five years, but will vary for each subject due to the number of predefined major cardiovascular events.
This is an oral medication. The study medication and allopurinol will be administered in several different dosages based on a person’s randomization.
You may be eligible to participate in this study if you:
- Are a male age > 50 years or female > 55 years of age and at least two years post menopausal
- Have been diagnosed with gout and have a documented medical history of a major cardiovascular disease
- Have no history of cancer, peptic ulcer disease, drug abuse or alcohol abuse within five years prior to study entry
- Have no significant medical condition and/or conditions that would interfere with the treatment, safety, or compliance with the protocol
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.